The Italian company will acquire EUSA for €750m, helping to broaden its rare disease franchise into the oncology arena.

The firm’s sole nephrological asset has demonstrated proof of concept, helping advance the novel gene-targeted therapy into pivotal development early next year.

The company’s lead candidate, AP1189, has shown promise in a mid-stage rheumatoid arthritis study, sparking plans for an imminent strategic business collaboration. 

NRx’s BriLife has demonstrated strong potential in early data from a mid-stage COVID-19 trial, spurring the company on to begin a Phase IIb/III study as soon as possible.

Pfizer and BioNTech’s Comirnaty supply under existing agreements will continue as planned despite anticipated expansion into a new child sub-population in Europe.

Increases in liver enzymes and fat could dampen approval prospects despite vupanorsen meeting its mid-stage primary endpoint, some analysts have said.